Search
Pennsylvania Paid Clinical Trials
A listing of 3310 clinical trials in Pennsylvania actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 3310
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Popular Cities
Pennsylvania is currently home to 3310 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Dilated Cardiomyopathy (DCM) Research Study
Recruiting
If you are identified as eligible for investigational genetic testing, you will be sent a saliva collection kit to your home. Once you have completed and returned your kit to Sano Genetics, your sample will be tested for a specific genetic pathway called BAG3.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Conditions:
Dilated Cardiomyopathy (DCM)
Cardiovascular Diseases
Cardiomyopathy
Cardiovascular Disease
Heart Failure
Featured Trial
Parkinson's Disease: Genetic Testing and Clinical Trial
Recruiting
Sano is launching a new study to understand the genetics of Parkinson’s and give researchers the data they need to better understand this condition. By participating, you will support cutting-edge research and help pave the way for future breakthroughs. You may be referred to participate in a clinical trial.
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
By participating in this study, you can:
- Receive a first-of-its-kind, Parkinson's genetic test at home, cost free
- Understand your eligibility for an investigational clinical trial in Parkinson's disease
- Receive notifications for future research opportunities
- Access expert, condition-specific educational materials tailored to Parkinson's disease
Conditions:
Parkinson's Disease
Parkinson Disease
Parkinson's Disease (PD)
Idiopathic Parkinson's Disease
Parkinsonian Disorders
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Recruiting
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Local Institution - 0657, York, Pennsylvania
Conditions: Carcinoma, Non-Small-Cell Lung
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Metastatic Colorectal Cancer
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Recruiting
This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania
Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
E-Mindfulness Approaches for Living After Breast Cancer
Recruiting
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemoth... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/01/2025
Locations: NRG Oncology, Pittsburgh, Pennsylvania
Conditions: Breast Cancer, Depression
Avexitide for Treatment of Post-Bariatric Hypoglycemia
Recruiting
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by reduction of hypoglycemic events. The study includes a Screening period with a Run-in period (of up to 6- and 3-weeks, respectively); a randomized, double-blind, placebo-controlled study treatment period of 16 weeks; and a two-part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Penn Medicine University City, Philadelphia, Pennsylvania
Conditions: Post Bariatric Hypoglycemia
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Recruiting
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Chester, Pennsylvania
Conditions: Chronic Kidney Disease and Hypertension
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Recruiting
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, and who have an abnormal change (mutation) in the IDH2 gene. This gene mutation can cause AML to grow and spread. This trial is being done to see if adding enasidenib to the usual treatment can help mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Acute Myeloid Leukemia
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
Recruiting
This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).
Gender:
ALL
Ages:
6 months and above
Trial Updated:
07/01/2025
Locations: Krystal Biotech, Pittsburgh, Pennsylvania
Conditions: Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Recruiting
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Metastatic HER2-positive Breast Cancer
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Recruiting
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: GSK Investigational Site, Philadelphia, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Recruiting
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, KRAS G12C, Pancreatic Cancer